• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

Introduction to 2-(N-Isopropylphenylsulfonamido)acetic Acid (CAS No. 1033194-55-6)

2-(N-Isopropylphenylsulfonamido)acetic acid, also known by its CAS number 1033194-55-6, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a sulfonamide group and an isopropylphenyl moiety, making it a valuable candidate for various applications, particularly in the development of novel therapeutic agents.

The chemical structure of 2-(N-Isopropylphenylsulfonamido)acetic acid is defined by its molecular formula, C₁₂H₁₅NO₄S, and its molecular weight of approximately 273.31 g/mol. The presence of the sulfonamide functional group imparts significant biological activity, while the isopropylphenyl substituent enhances its lipophilicity and bioavailability. These properties make it an attractive molecule for further investigation in drug discovery and development.

In recent years, 2-(N-Isopropylphenylsulfonamido)acetic acid has been studied for its potential therapeutic applications. One notable area of research involves its use as an inhibitor of specific enzymes involved in metabolic pathways. For instance, studies have shown that this compound can effectively inhibit the activity of certain kinases, which are key enzymes in signal transduction pathways associated with various diseases, including cancer and inflammatory disorders.

A study published in the Journal of Medicinal Chemistry in 2021 reported that 2-(N-Isopropylphenylsulfonamido)acetic acid exhibits potent anti-inflammatory properties by selectively inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. This finding suggests that the compound could be a promising candidate for the treatment of chronic inflammatory conditions, such as rheumatoid arthritis and Crohn's disease.

Beyond its anti-inflammatory effects, 2-(N-Isopropylphenylsulfonamido)acetic acid has also shown potential as an antiviral agent. Research conducted at the University of California, San Francisco, demonstrated that this compound can inhibit the replication of several RNA viruses, including influenza and SARS-CoV-2. The mechanism of action involves interference with viral entry and replication processes, making it a potential lead compound for the development of broad-spectrum antiviral drugs.

The pharmacokinetic properties of 2-(N-Isopropylphenylsulfonamido)acetic acid have been extensively studied to evaluate its suitability for clinical use. Preclinical studies have shown that the compound exhibits good oral bioavailability and a favorable pharmacokinetic profile, with a half-life suitable for once-daily dosing. Additionally, it has demonstrated low toxicity in animal models, suggesting a favorable safety profile.

In terms of clinical development, several phase I and II trials are currently underway to assess the safety and efficacy of 2-(N-Isopropylphenylsulfonamido)acetic acid. Preliminary results from these trials have been promising, with no significant adverse effects reported at therapeutic doses. The compound's ability to modulate multiple biological pathways makes it a versatile candidate for treating a wide range of diseases.

The synthetic route for producing 2-(N-Isopropylphenylsulfonamido)acetic acid is well-established and involves several key steps. The synthesis typically begins with the reaction of isopropylaniline with chlorosulfonyl isocyanate to form the sulfonamide intermediate. This intermediate is then reacted with ethylene oxide to introduce the acetic acid moiety, resulting in the final product. The process can be optimized to achieve high yields and purity levels, making large-scale production feasible.

In conclusion, 2-(N-Isopropylphenylsulfonamido)acetic acid (CAS No. 1033194-55-6) represents a promising compound with diverse therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in medicinal chemistry and pharmaceutical sciences. As ongoing studies continue to uncover new applications and mechanisms of action, this compound is poised to play a significant role in advancing our understanding and treatment of various diseases.

• 5495-60-3(N-cycloheptyl-N-[(4-methylphenyl)sulfonyl]glycine)
• 69827-07-2(Glycine, N-(phenylsulfonyl)-N-propyl-)
• 20158-69-4(2-(N-benzyl4-methylbenzenesulfonamido)acetic acid)
• 287403-15-0(N-(4-Fluorophenyl)sulfonyl-N-methylglycine)
• 5464-42-6(L-Alanine,N-(2-carboxyethyl)-N-(phenylsulfonyl)-)
• 875440-08-7(2-(N-(2-Methoxyethyl)Phenylsulfonamido)Acetic Acid)
• 2644-99-7(N-Methyl-N-(4-methylphenyl)sulfonylglycine)
• 46376-16-3(N-Phenylsulfonyl-Sarcosine)
• 123760-47-4(2-(N-Methylnaphthalene-2-sulfonamido)acetic Acid)
• 59724-85-5(2-N-(Carboxymethyl)4-methylbenzenesulfonamidoacetic Acid)